ArticleEuropean urology oncology2023

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.

Bradley McGregor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.